期刊： DRUGS OF TODAY, 2021; 57 (6)
Small cell lung cancer (SCLC) is a rapidly progressive, aggressive metastatic and lethal subtype of lung cancer. Unfortunately, there has been little ......
期刊： DRUGS OF TODAY, 2021; 57 (4)
Non-small cell lung cancer (NSCLC) is one of the most devastating cancers with high mortality worldwide. By inhibiting the activity of specific molecu......
期刊： DRUGS OF TODAY, 2020; 56 (7)
Gastric cancer is one of the most common malignant tumors in the world. In China, its morbidity and mortality are second only to lung cancer. Chemothe......
期刊： DRUGS OF TODAY, 2020; 56 (12)
Classical Hodgkin's lymphoma (cHL) is an unusual lymphoid neoplasm, and nearly 50% of patients still relapse after standard therapy. Programmed cell d......
期刊： DRUGS OF TODAY, 2018; 54 (7)
The 9th Annual Biosimilar Asia, an event hosted by ICB Asia, was held at the Hilton Shanghai Hongqiao from May 16 to 17. It was held simultaneously wi......
期刊： DRUGS OF TODAY, 2022; 58 (1)
Systemic lupus erythematosus (SLE) is a chronic auto immune disease, in which aberrant immune cells and proinflammatory mediators act as key players i......
期刊： DRUGS OF TODAY, 2022; 58 (10)
Antibody-drug conjugates (ADCs), a combination of cyto-toxic drugs and antibodies, have emerged as a rising star in cancer therapy. Disitamab vedotin ......
期刊： DRUGS OF TODAY, 2022; 58 (6)
Acute lymphoblastic leukemia (ALL) is a neoplastic disease characterized by the malignant proliferation of lymphoid cells in the blood and bone marrow......
期刊： DRUGS OF TODAY, 2022; 58 (2)
Ibrutinib, an oral small-molecule targeted drug, has been the first Bruton tyrosine kinase (BTK) inhibitor in the world to be approved for the market.......
期刊： DRUGS OF TODAY, 2022; 58 (5)
Cervical cancer is one of the most common gynecological malignancies. At present, cytotoxic chemotherapeutic drugs and immunotherapy are the main ther......
期刊： DRUGS OF TODAY, 2022; 58 (3)
The introduction of new classes of drugs for the treatment of multiple myeloma (MM) in the past 2 decades, such as proteasome inhibitors, immunomodula......
期刊： DRUGS OF TODAY, 2022; 58 (4)
Sotorasib, a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C mutation, was approved by the U.S. Food and Drug A......
期刊： DRUGS OF TODAY, 2017; 53 (11)
On August 30, 2017, the U.S. Food and Drug Administration (FDA) approved Novartis' tisagenlecleucel (CTL-019, Kymriah), which is a synthetic bioimmune......
期刊： DRUGS OF TODAY, 2017; 53 (3)
Chidamide is the first oral subtype-selective histone deacetylase inhibitor (HDACI) approved in China as well as the first HDACI of the benzamide clas......
